BeiGene’s Oncology Market 'Disruption' Gains Pace Despite Tevimbra Travails

The Sino-American company believes faster, lower-cost R&D and competitive pricing and access will give it an edge in oncology. Its chief commercial officer for North America and Europe told Scrip how it is now looking to repeat the success of Brukinsa and finally launch its much-delayed PD-1 inhibitor Tevimbra.